Find HDV and Determine Its Status in Turkey
Launched by YAŞAR BAYINDIR, MD · Jan 31, 2024
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Find HDV and Determine Its Status in Turkey," is focused on understanding how common hepatitis Delta virus (HDV) infections are in certain areas of southeastern Turkey and how these infections affect patients' health. Researchers will train 250 family doctors in cities like Diyarbakir and Batman to help them identify patients with HDV, hepatitis B (HBV), hepatitis C (HCV), and HIV. They will also learn how to check for liver damage using a simple, non-invasive method.
To participate in this study, individuals must be at least 18 years old, be positive for hepatitis B (meaning they have the virus in their blood) for at least six months, and be a citizen of Turkey. There are no other specific requirements that would exclude someone from joining. Participants can expect to receive information about their health and the opportunity to help improve the understanding and diagnosis of these infections in their community. This trial is currently looking for volunteers, and everyone is welcome to join, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (Age≥18)
- • Being HBsAg positive for at least six months
- • Being a citizen of the Republic of Türkiye
- Exclusion Criteria:
- • There are no exclusion criteria in this study.
About Yaşar Bayındır, Md
Dr. Yaşar Bayındır, MD, is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic solutions, Dr. Bayındır leads initiatives that bridge the gap between scientific discovery and clinical application. His expertise encompasses a wide range of therapeutic areas, and he is dedicated to fostering collaboration among researchers, healthcare professionals, and regulatory bodies to ensure the integrity and success of clinical trials. Dr. Bayındır's leadership is characterized by a patient-centric approach, emphasizing the importance of ethical standards and rigorous methodologies in the pursuit of breakthrough treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Turkey
Diyarbakır, Turkey
Patients applied
Trial Officials
Mustafa Kemal Çelen, MD
Principal Investigator
Dicle University, Medical Faculty, Department of Infectious Diseases
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported